<a href=Novo Nordisk” class=”halfleft” height=”225″ src=”https://www.pharmaceutical-technology.com/wp-content/uploads/image-digitalinsightresearch/Archive/nri/pharma/NovoNordisk.jpg” width=”400″ />

Novo Nordisk has broken ground on a new diabetes medicine production facility in North Carolina, US, which will be built at a cost of $1.8bn.

The investment is part of the company’s plans to invest nearly $2bn in production facilities in Clayton, US and Malov and Kalundborg, Denmark.

When operational in 2020, the facility will produce active pharmaceutical ingredients (API) for a range of Novo Nordisk’s current and future GLP-1 and insulin medicines.

North Carolina governor Pat McCrory said: "Novo Nordisk’s billion dollar decision to bring this landmark manufacturing facility to North Carolina underscores its commitment to our state and confidence in our state’s talent."

The proposed facility is being built adjacent to Novo Nordisk’s existing plant in Clayton, which is involved in the formulation, filling and packaging of diabetes medicines.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The plant also assembles and packages the company’s FlexPen and FlexTouch prefilled insulin devices for the US market.

"This site will play a vital role in enabling us to meet the needs of people living with diabetes in the US for years to come."

McCrory added: "This expansion of the current site and workforce highlights our ability to be a leader in biomanufacturing at the global level."

The production expansion will create 700 new jobs with another 2,500 jobs to be created during the construction phase of the new plant.

Novo Nordisk president Lars Rebien Sørensen said: "As the prevalence of diabetes has grown in the US, so too has the demand for effective treatments.

"It gives me great pride to break ground on our new facility site in Clayton where we have an existing, strong organisation.

"This site will play a vital role in enabling us to meet the needs of people living with diabetes in the US for years to come."

With nearly 39,700 employees in 75 countries, Novo Nordisk markets its products in more than 180 countries.


Image: Novo Nordisk’s existing plant in Clayton assembles and packages the company’s FlexPen and FlexTouch prefilled insulin devices. Photo: courtesy of Novo Nordisk.